Publications

Disouza, J, Kumbhar, P, Manjappa, A, Nadaf, S, Kumbar, V, Singh, SK, Dua, K & Patravale, V 2024, 'Characterization of polymers' in Polymers for Pharmaceutical and Biomedical Applications, Elsevier, pp. 107-129.
View/Download from: Publisher's site

Patel, A, Vora, H, Prajapati, BG, Singh, SK, Dua, K, Patel, A & Patel, S 2024, 'Decipher the role of cancer stem cells in colorectal cancer based on molecular pathology and its clinical significance' in Colorectal Cancer, Elsevier, pp. 533-555.
View/Download from: Publisher's site

Verma, N, Kumar, J, Kanojia, N, Thapa, K & Dua, K 2024, 'Nutraceuticals and phytoceuticals in the treatment of colon disorders' in Advanced Drug Delivery Systems for Colonic Disorders, Elsevier, pp. 223-241.
View/Download from: Publisher's site

Verma, N, Thapa, K, Kanojia, N, Sood, P, Kumar, J, Thakur, N & Dua, K 2024, 'OX40 and CD40 Agonists for the Treatment of Lung Cancer' in Immunotherapy Against Lung Cancer, Springer Nature Singapore, pp. 181-199.
View/Download from: Publisher's site

Acharya, M, Singh, N, Gupta, G, Tambuwala, MM, Aljabali, AAA, Chellappan, DK, Dua, K & Goyal, R 2024, 'Vitamin D, Calbindin, and calcium signaling: Unraveling the Alzheimer's connection', Cellular Signalling, vol. 116, pp. 111043-111043.
View/Download from: Publisher's site

Athalye, M, Teli, D, Chorawala, M, Sharma, A, Patel, R, Dua, K, Singh, SK, Gupta, G & Patel, M 2024, 'Apolipoprotein E3 functionalized lipid-drug conjugated nanoparticles of Levetiracetam for enhanced delivery to the brain: In-vitro cell line studies and in-vivo study', International Journal of Biological Macromolecules, vol. 254, pp. 127799-127799.
View/Download from: Publisher's site
View description>>

A significant portion of brain-tumor patients suffer from 'brain-tumor-related epilepsy (BTE)' which results in depression, anxiety and hampered quality of life. Conventional anti-epileptic drugs indicate negative interaction with other drugs augmenting the poor outcome of overall therapy. Levetiracetam (LVM) has evidenced effectiveness for BTE but its hydrophilicity restricts the passage into blood-brain barrier. The majority of lipid nanoparticles fails to load hydrophilic drug sufficiently. Therefore, lipid-drug conjugates (LDC) were synthesized using stearic acid via amide bond formation confirmed by FTIR and NMR. The nanoparticles of synthesized LDC were prepared by solvent injection method followed by functionalization with Apolipoprotein E3 (ApoE3@LDC-NP). The nanoparticles were characterized by DSC, XRD, particle size (131.6 ± 1.24 nm), zeta potential (-15.6 ± 0.09 mV), and for storage stability. In-vitro release study indicated initial burst release of 20 ± 0.63 % followed by sustained release up to 30 h (66 ± 1.40 %) for ApoE3@LDC-NP. The cell-line study on HEK293 indicated no significant cytotoxic effect and greater cell uptake through U87MG cell line. The pharmacokinetic and bio-distribution study indicated 2.5-fold greater brain-targeting of ApoE3@LDC-NP as compared to LVM solution. It proved safe in the haemolysis study and exhibited the absence of tissue necrosis. Thus, ApoE3@LDC-NP might be a promising approach for effective brain-targeting of LVM for improved clinical response in BTE.

Bangar, A, Khan, H, Kaur, A, Dua, K & Singh, TG 2024, 'Understanding mechanistic aspect of the therapeutic role of herbal agents on neuroplasticity in cerebral ischemic-reperfusion injury', Journal of Ethnopharmacology, vol. 319, pp. 117153-117153.
View/Download from: Publisher's site
View description>>

ETHNOPHARMACOLOGICAL RELEVANCE: Stroke is one of the leading causes of death and disability. The only FDA-approved therapy for treating stroke is tissue plasminogen activator (tPA), exhibiting a short therapeutic window. Due to this reason, only a small number of patients can be benefitted in this critical period. In addition, the use of endovascular interventions may reverse vessel occlusion more effectively and thus help further improve outcomes in experimental stroke. During recovery of blood flow after ischemia, patients experience cognitive, behavioral, affective, emotional, and electrophysiological changes. Therefore, it became the need for an hour to discover a novel strategy for managing stroke. The drug discovery process has focused on developing herbal medicines with neuroprotective effects via modulating neuroplasticity. AIM OF THE STUDY: We gather and highlight the most essential traditional understanding of therapeutic plants and their efficacy in cerebral ischemia-reperfusion injury. In addition, we provide a concise summary and explanation of herbal drugs and their role in improving neuroplasticity. We review the pharmacological activity of polyherbal formulations produced from some of the most frequently referenced botanicals for the treatment of cerebral ischemia damage. MATERIALS AND METHODS: A systematic literature review of bentham, scopus, pubmed, medline, and embase (elsevier) databases was carried out with the help of the keywords like neuroplasticity, herbal drugs, neural progenitor cells, neuroprotection, stem cells. The review was conducted using the above keywords to understand the therapeutic and mechanistic role of herbal neuroprotective agents on neuroplasticity in cerebral ischemic-reperfusion injury. RESULTS: Neuroplasticity emerged as an alternative to improve recovery and management after cerebral ischemic reperfusion injury. Neuroplasticity is a physiological process throughout one's life in response to any stimuli and...

Bashir, B, Alam, S, Khandale, N, Birla, D, Vishwas, S, Pandey, NK, Gupta, G, Paudel, KR, Dureja, H, Kumar, P, Singh, TG, Kuppusamy, G, Zacconi, FC, Pinto, TDJA, Dhanasekaran, M, Gulati, M, Dua, K & Singh, SK 2024, 'Opening avenues for treatment of neurodegenerative disease using post-biotics: Breakthroughs and bottlenecks in clinical translation', Ageing Research Reviews, vol. 95, pp. 102236-102236.
View/Download from: Publisher's site

Bashir, B, Mittal, S, Muthukumar, A, Vishwas, S, Pandey, NK, Gulati, M, Gupta, G, Dhanasekaran, M, Kumar, P, Dureja, H, Veiga, F, Paiva-Santos, AC, Adams, J, Dua, K & Singh, SK 2024, 'Harnessing the neuroprotective effect of oral administration of benfotiamine in MPTP induced Parkinson's disease in rats', European Journal of Pharmacology, vol. 962, pp. 176234-176234.
View/Download from: Publisher's site
View description>>

The study was performed to evaluate the neuroprotective effects of Benfotiamine (BFT) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) in rats. The rats were given daily doses of BFT (100mg/kg, 200mg/kg) through oral administration for 42 days. The rats were given a single bilateral dosage of MPTP (0.1 mg/nostril) intranasally once before the drug treatment to induce PD. On day 42, the animals were subjected to various behavioral paradigms. Post-treatment with BFT for 42 days significantly improved the motor and nonmotor fluctuations of MPTP. The results demonstrated that treatment with BFT ameliorated MPTP-induced disorders in behavior, body balance, and dopamine levels in the mid-brain. Among the post-treated groups, a high dose of BFT was the most effective treatment. Mean values are indicated in ±SEM, n = 5***(p < 0.001) when compared with the vehicle control, n = 5 ### (p < 0.001) when compared with the disease control; (p < 0.001) when compared with the BFT per se; (p < 0.001) when compared with the low dose of BFT; (p < 0.001) when compared with the high dose of BFT. Our finding suggests that BFT contributed to superior antioxidant, and anti-inflammatory and could be a novel therapeutic method for PD management. In conclusion, BFT could be a potential drug candidate for curbing and preventing PD.

Bhat, AA, Afzal, M, Goyal, A, Gupta, G, Thapa, R, almalki, WH, Kazmi, I, Alzarea, SI, Shahwan, M, Paudel, KR, Ali, H, Sahu, D, Prasher, P, Singh, SK & Dua, K 2024, 'The impact of formaldehyde exposure on lung inflammatory disorders: Insights into asthma, bronchitis, and pulmonary fibrosis', Chemico-Biological Interactions, vol. 394, pp. 111002-111002.
View/Download from: Publisher's site

Bhat, AA, Gupta, G, Dahiya, R, Thapa, R, Gahtori, A, Shahwan, M, Jakhmola, V, Tiwari, A, Kumar, M, Dureja, H, Singh, SK, Dua, K, Kumarasamy, V & Subramaniyan, V 2024, 'CircRNAs: Pivotal modulators of TGF-β signalling in cancer pathogenesis', Non-coding RNA Research, vol. 9, no. 2, pp. 277-287.
View/Download from: Publisher's site

Bhat, AA, Riadi, Y, Afzal, M, Bansal, P, Kaur, H, Deorari, M, Ali, H, Shahwan, M, almalki, WH, Kazmi, I, Alzarea, SI, Dureja, H, Singh, SK, Dua, K & Gupta, G 2024, 'Exploring ncRNA-mediated pathways in sepsis-induced pyroptosis', Pathology - Research and Practice, vol. 256, pp. 155224-155224.
View/Download from: Publisher's site

Chan, M, Ghadieh, C, Irfan, I, Khair, E, Padilla, N, Rebeiro, S, Sidgreaves, A, Patravale, V, Disouza, J, Catanzariti, R, Pont, L, Williams, K, De Rubis, G, Mehndiratta, S, Dhanasekaran, M & Dua, K 2024, 'Exploring the influence of the microbiome on the pharmacology of anti-asthmatic drugs', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 397, no. 2, pp. 751-762.
View/Download from: Publisher's site
View description>>

AbstractThe microbiome is increasingly implicated in playing a role in physiology and pharmacology; in this review, we investigate the literature on the possibility of bacterial influence on the pharmacology of anti-asthmatic drugs, and the potential impact this has on asthmatic patients. Current knowledge in this area of research reveals an interaction between the gut and lung microbiome and the development of asthma. The influence of microbiome on the pharmacokinetics and pharmacodynamics of anti-asthmatic drugs is limited; however, understanding this interaction will assist in creating a more efficient treatment approach. This literature review highlighted that bioaccumulation and biotransformation in the presence of certain gut bacterial strains could affect drug metabolism in anti-asthmatic drugs. Furthermore, the bacterial richness in the lungs and the gut can influence drug efficacy and could also play a role in drug response. The implications of the above findings suggest that the microbiome is a contributing factor to an individuals’ pharmacological response to anti-asthmatic drugs. Hence, future directions for research should follow investigating how these processes affect asthmatic patients and consider the role of the microbiome on drug efficacy and modify treatment guidelines accordingly.

De Rubis, G, Paudel, KR, Allam, VSRR, Malyla, V, Subramaniyan, V, Singh, SK, Panth, N, Gupta, G, Hansbro, PM, Chellappan, DK & Dua, K 2024, 'Involvement of osteopontin, EpCAM, estrogen receptor-alpha, and carbonic anhydrase IX protein in managing lung cancer via Berberine-loaded liquid crystalline nanoparticles', Pathology - Research and Practice, vol. 253, pp. 154971-154971.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Yeung, S, Agarwal, V, Hansbro, PM, Oliver, BGG & Dua, K 2024, 'Ribavirin attenuates carcinogenesis by downregulating IL-6 and IL-8 in vitro in human lung adenocarcinoma', Pathology - Research and Practice, vol. 253, pp. 155038-155038.
View/Download from: Publisher's site

De Rubis, G, Paudel, KR, Yeung, S, Mohamad, S, Sudhakar, S, Singh, SK, Gupta, G, Hansbro, PM, Chellappan, DK, Oliver, BGG & Dua, K 2024, '18-β-glycyrrhetinic acid-loaded polymeric nanoparticles attenuate cigarette smoke-induced markers of impaired antiviral response in vitro', Pathology - Research and Practice, vol. 257, pp. 155295-155295.
View/Download from: Publisher's site

Hussain, MS, Altamimi, ASA, Afzal, M, almalki, WH, Kazmi, I, Alzarea, SI, Saleem, S, Prasher, P, Oliver, B, Singh, SK, MacLoughlin, R, Dua, K & Gupta, G 2024, 'From carcinogenesis to therapeutic avenues: lncRNAs and mTOR crosstalk in lung cancer', Pathology - Research and Practice, vol. 253, pp. 155015-155015.
View/Download from: Publisher's site

Hussain, MS, Gupta, G, Mishra, R, Patel, N, Gupta, S, Alzarea, SI, Kazmi, I, Kumbhar, P, Disouza, J, Dureja, H, Kukreti, N, Singh, SK & Dua, K 2024, 'Unlocking the secrets: Volatile Organic Compounds (VOCs) and their devastating effects on lung cancer', Pathology - Research and Practice, vol. 255, pp. 155157-155157.
View/Download from: Publisher's site

Hussain, MS, Gupta, G, Samuel, VP, Almalki, WH, Kazmi, I, Alzarea, SI, Saleem, S, Khan, R, Altwaijry, N, Patel, S, Patel, A, Singh, SK & Dua, K 2024, 'Immunopathology of herpes simplex virus‐associated neuroinflammation: Unveiling the mysteries', Reviews in Medical Virology, vol. 34, no. 1, p. e2491.
View/Download from: Publisher's site
View description>>

AbstractThe immunopathology of herpes simplex virus (HSV)‐associated neuroinflammation is a captivating and intricate field of study within the scientific community. HSV, renowned for its latent infection capability, gives rise to a spectrum of neurological expressions, ranging from mild symptoms to severe encephalitis. The enigmatic interplay between the virus and the host's immune responses profoundly shapes the outcome of these infections. This review delves into the multifaceted immune reactions triggered by HSV within neural tissues, intricately encompassing the interplay between innate and adaptive immunity. Furthermore, this analysis delves into the delicate equilibrium between immune defence and the potential for immunopathology‐induced neural damage. It meticulously dissects the roles of diverse immune cells, cytokines, and chemokines, unravelling the intricacies of neuroinflammation modulation and its subsequent effects. By exploring HSV's immune manipulation and exploitation mechanisms, this review endeavours to unveil the enigmas surrounding the immunopathology of HSV‐associated neuroinflammation. This comprehensive understanding enhances our grasp of viral pathogenesis and holds promise for pioneering therapeutic strategies designed to mitigate the neurological ramifications of HSV infections.

Hussain, MS, Moglad, E, Afzal, M, Bansal, P, Kaur, H, Deorari, M, Ali, H, Shahwan, M, Hassan almalki, W, Kazmi, I, Alzarea, SI, Singh, SK, Dua, K & Gupta, G 2024, 'Circular RNAs in the KRAS pathway: Emerging players in cancer progression', Pathology - Research and Practice, vol. 256, pp. 155259-155259.
View/Download from: Publisher's site

Jessamine, V, Mehndiratta, S, De Rubis, G, Paudel, KR, Shetty, S, Suares, D, Chellappan, DK, Oliver, BG, Hansbro, PM & Dua, K 2024, 'The application of nanoparticles as advanced drug delivery systems in Attenuating COPD', Heliyon, vol. 10, no. 3, pp. e25393-e25393.
View/Download from: Publisher's site

Kakoty, V, Sarathlal, KC, Kaur, P, Wadhwa, P, Vishwas, S, Khan, FR, Alhazmi, AYM, Almasoudi, HH, Gupta, G, Chellappan, DK, Paudel, KR, Kumar, D, Dua, K & Singh, SK 2024, 'Unraveling the role of glial cell line–derived neurotrophic factor in the treatment of Parkinson’s disease', Neurological Sciences, vol. 45, no. 4, pp. 1409-1418.
View/Download from: Publisher's site

Kokkinis, S, Singh, M, Paudel, KR, De Rubis, G, Bani Saeid, A, Jessamine, V, Datsyuk, J, Singh, SK, Vishwas, S, Adams, J, Hansbro, PM, Oliver, B, Gupta, G, Dureja, H & Dua, K 2024, 'Plant-based therapeutics for chronic obstructive pulmonary diseases: Nanoformulation strategies to overcome delivery challenges', Food Bioscience, vol. 58, pp. 103761-103761.
View/Download from: Publisher's site

Lee, JY, Bhandare, RR, Boddu, SHS, Shaik, AB, Saktivel, LP, Gupta, G, Negi, P, Barakat, M, Singh, SK, Dua, K & Chellappan, DK 2024, 'Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer', Biomedicine & Pharmacotherapy, vol. 173, pp. 116275-116275.
View/Download from: Publisher's site

Mahanur, VB, Rajge, RR, Vishwas, S, Chaitanya, MVNL, Salahuddin, Mishra, R, Pandey, NK, Singh, S, Baghel, DS, Gupta, G, Collet, T, Oguntibeju, OO, Adams, J, Dua, K & Singh, SK 2024, 'Development and validation of RP-HPLC method for estimation of quercetin present in hydro alcoholic extract of Erigeron bonariensis Linn.', South African Journal of Botany, vol. 167, pp. 182-189.
View/Download from: Publisher's site

Manandhar, B, Pandzic, E, Deshpande, N, Chen, S-Y, Wasinger, VC, Kockx, M, Glaros, EN, Ong, KL, Thomas, SR, Wilkins, MR, Whan, RM, Cochran, BJ & Rye, K-A 2024, 'ApoA-I Protects Pancreatic β-Cells From Cholesterol-Induced Mitochondrial Damage and Restores Their Ability to Secrete Insulin', Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 44, no. 2.
View/Download from: Publisher's site
View description>>

BACKGROUND: High cholesterol levels in pancreatic β-cells cause oxidative stress and decrease insulin secretion. β-cells can internalize apo (apolipoprotein) A-I, which increases insulin secretion. This study asks whether internalization of apoA-I improves β-cell insulin secretion by reducing oxidative stress. METHODS: Ins-1E cells were cholesterol-loaded by incubation with cholesterol-methyl-β-cyclodextrin. Insulin secretion in the presence of 2.8 or 25 mmol/L glucose was quantified by radioimmunoassay. Internalization of fluorescently labeled apoA-I by β-cells was monitored by flow cytometry. The effects of apoA-I internalization on β-cell gene expression were evaluated by RNA sequencing. ApoA-I-binding partners on the β-cell surface were identified by mass spectrometry. Mitochondrial oxidative stress was quantified in β-cells and isolated islets with MitoSOX and confocal microscopy. RESULTS: An F 1 -ATPase β-subunit on the β-cell surface was identified as the main apoA-I-binding partner. β-cell internalization of apoA-I was time-, concentration-, temperature-, cholesterol-, and F 1 -ATPase β-subunit-dependent. β-cells with internalized apoA-I (apoA-I + cells) had higher cholesterol and cell surface F 1 -ATPase β-subunit levels than β-cells without internalized apoA-I (apoA-I − cells). The internalized apoA-I colocalized with mitochondria and was associated with reduced oxidative stress and increased insulin secreti...

Manandhar, B, Paudel, KR, Clarence, DD, De Rubis, G, Madheswaran, T, Panneerselvam, J, Zacconi, FC, Williams, KA, Pont, LG, Warkiani, ME, MacLoughlin, R, Oliver, BG, Gupta, G, Singh, SK, Chellappan, DK, Hansbro, PM & Dua, K 2024, 'Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 397, no. 1, pp. 343-356.
View/Download from: Publisher's site
View description>>

AbstractLung cancer is the second most prevalent type of cancer and is responsible for the highest number of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) makes up the majority of lung cancer cases. Zerumbone (ZER) is natural compound commonly found in the roots of Zingiber zerumbet which has recently demonstrated anti-cancer activity in both in vitro and in vivo studies. Despite their medical benefits, ZER has low aqueous solubility, poor GI absorption and oral bioavailability that hinders its effectiveness. Liquid crystalline nanoparticles (LCNs) are novel drug delivery carrier that have tuneable characteristics to enhance and ease the delivery of bioactive compounds. This study aimed to formulate ZER-loaded LCNs and investigate their effectiveness against NSCLC in vitro using A549 lung cancer cells. ZER-LCNs, prepared in the study, inhibited the proliferation and migration of A549 cells. These inhibitory effects were superior to the effects of ZER alone at a concentration 10 times lower than that of free ZER, demonstrating a potent anti-cancer activity of ZER-LCNs. The underlying mechanisms of the anti-cancer effects by ZER-LCNs were associated with the transcriptional regulation of tumor suppressor genes P53 and PTEN, and metastasis-associated gene KRT18. The protein array data showed downregulation of several proliferation associated proteins such as AXL, HER1, PGRN, and BIRC5 and metastasis-associated proteins such as DKK1, CAPG, CTSS, CTSB, CTSD, and PLAU. This study provides evidence of potential for increasing the potency and effectiveness of ZER with LCN formulation and developing ZER-LCNs as a treatment strategy for mitigation and treatment of NSCLC.

Osman, M, Khalil, J, El-Bahri, M, Swalah Mcdahrou, J, Fahda, R, Mustafa, R, Ooi, A, Attayee, M, Catanzariti, R, Pont, L, Williams, K, Yeung, S, Dua, K, De Rubis, G & Loebenberg, R 2024, 'Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations', Chemico-Biological Interactions, vol. 394, pp. 110988-110988.
View/Download from: Publisher's site

Paramjot, Wadhwa, S, Sharma, A, Singh, SK, Vishwas, S, Kumar, R, Singh, S, Dua, K, Chellappan, DK & Gupta, G 2024, 'A Comprehensive Review on the Role of Polymers in Ocular DrugDelivery', Current Drug Delivery, vol. 21, no. 1, pp. 16-37.
View/Download from: Publisher's site
View description>>

Abstract:Amongst different routes of drug delivery systems, ophthalmic drug delivery still requires acareful investigation and strict parameter measurements because the eyes are one of the most sensitiveparts of the body and require special attention. The conventional systems for eyes lead to rapid eliminationof formulation and hence very small contact time on the ocular epithelium. The current review articlecovers various types of polymers used in ocular drug delivery along with their applications/limitations. Polymers are widely used by researchers in prodrug techniques and as a penetrationenhancer in ocular delivery. This article covers the role and use of different polymeric systems whichmakes the final formulation a promising candidate for ophthalmic drug delivery.:The researchers are still facing multiple challenges in order to maintain the therapeutic concentration ofthe drug in the eyes because of its complex structure. There are several barriers that further restrict theintraocular entry of the drug. In order to remove/reduce such challenges, these days various types ofpolymers are used for ocular delivery in order to develop different drug carrier systems for better efficacyand stability. The polymers used are highly helpful in increasing residence time by increasing theviscosity at the ocular epithelium layer. Such preparations also get easily permeated in ocular cells. Thecombination of different polymeric properties makes the final formulation stable with prolonged retention,high viscosity, high permeability, and better bioavailability, making the final formulation a promisingcandidate for ocular drug delivery.

Paudel, KR, Clarence, DD, Panth, N, Manandhar, B, De Rubis, G, Devkota, HP, Gupta, G, Zacconi, FC, Williams, KA, Pont, LG, Singh, SK, Warkiani, ME, Adams, J, MacLoughlin, R, Oliver, BG, Chellappan, DK, Hansbro, PM & Dua, K 2024, 'Zerumbone liquid crystalline nanoparticles protect against oxidative stress, inflammation and senescence induced by cigarette smoke extract in vitro', Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 397, no. 4, pp. 2465-2483.
View/Download from: Publisher's site
View description>>

AbstractThe purpose of this study was to evaluate the potential of zerumbone-loaded liquid crystalline nanoparticles (ZER-LCNs) in the protection of broncho-epithelial cells and alveolar macrophages against oxidative stress, inflammation and senescence induced by cigarette smoke extract in vitro. The effect of the treatment of ZER-LCNs on in vitro cell models of cigarette smoke extract (CSE)-treated mouse RAW264.7 and human BCi-NS1.1 basal epithelial cell lines was evaluated for their anti-inflammatory, antioxidant and anti-senescence activities using colorimetric and fluorescence-based assays, fluorescence imaging, RT-qPCR and proteome profiler kit. The ZER-LCNs successfully reduced the expression of pro-inflammatory markers including Il-6, Il-1β and Tnf-α, as well as the production of nitric oxide in RAW 264.7 cells. Additionally, ZER-LCNs successfully inhibited oxidative stress through reduction of reactive oxygen species (ROS) levels and regulation of genes, namely GPX2 and GCLC in BCi-NS1.1 cells. Anti-senescence activity of ZER-LCNs was also observed in BCi-NS1.1 cells, with significant reductions in the expression of SIRT1, CDKN1A and CDKN2A. This study demonstrates strong in vitro anti-inflammatory, antioxidative and anti-senescence activities of ZER-LCNs paving the path for this formulation to be translated into a promising therapeutic agent for chronic respiratory inflammatory conditions including COPD and asthma.

Paudel, KR, Mohamad, MSB, De Rubis, G, Reyes, R-J, Panth, N, Dureja, H, Gupta, G, Singh, SK, Madheswaran, T, Collet, T, Hansbro, PM, Dua, K & Chellappan, DK 2024, '18-β-Glycyrrhetinic acid encapsulated PLGA nanoparticles attenuate lung cancer proliferation and migration', Journal of Drug Delivery Science and Technology, vol. 95, pp. 105523-105523.
View/Download from: Publisher's site

Plakogiannis, FA, Weidmann, J, Fraser, B, Kwong, J, Asi, D, Kumar, P, Baldock, M, Naamo, J, Baluja, R, Catanzariti, R, Yeung, S, Pont, L, Williams, K, De Rubis, G, Dua, K & Bukhari, NI 2024, 'Investigation of smoking on the antiplatelet response to clopidogrel: Unravelling the Smoker’s Paradox.', Pathology - Research and Practice, pp. 155290-155290.
View/Download from: Publisher's site

Prajapat, VM, Aalhate, M, Sriram, A, Mahajan, S, Maji, I, Gupta, U, Kumari, D, Singh, K, Kalia, NP, Dua, K, Singh, SK & Singh, PK 2024, 'Amphotericin B loaded nanoemulsion: Optimization, characterization and in-vitro activity against L. donovani promastigotes', Parasitology International, vol. 100, pp. 102848-102848.
View/Download from: Publisher's site

Prasher, P, Sharma, M, Agarwal, V, Singh, SK, Gupta, G, Dureja, H & Dua, K 2024, 'Cationic cycloamylose based nucleic acid nanocarriers', Chemico-Biological Interactions, vol. 395, pp. 111000-111000.
View/Download from: Publisher's site

Saeid, AB, De Rubis, G, Williams, KA, Yeung, S, Chellappan, DK, Singh, SK, Gupta, G, Hansbro, PM, Shahbazi, M-A, Gulati, M, Kaur, IP, Santos, HA, Paudel, KR & Dua, K 2024, 'Revolutionising Lung Health: Exploring the Latest Breakthroughs and Future Prospects of Synbiotic Nanostructures in Lung Diseases', Chemico-Biological Interactions, pp. 111009-111009.
View/Download from: Publisher's site

Shaikh, MAJ, Altamimi, ASA, Afzal, M, Gupta, G, Singla, N, Gilhotra, R, almalki, WH, Kazmi, I, Alzarea, SI, Prasher, P, Singh, SK & Dua, K 2024, 'Unraveling the impact of miR-21 on apoptosis regulation in glioblastoma', Pathology - Research and Practice, vol. 254, pp. 155121-155121.
View/Download from: Publisher's site

Sharma, DS, Wadhwa, S, Gulati, M, Kumar, B, Chitranshi, N, Gupta, VK, Alrouji, M, Alhajlah, S, AlOmeir, O, Vishwas, S, Khursheed, R, Saini, S, Kumar, A, Parveen, SR, Gupta, G, Zacconi, F, Chellappan, DK, Morris, A, Loebenberg, R, Dua, K & Singh, SK 2024, 'Corrigendum to - Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug, Vol. 224, 1 January 2023, Pages 810-830', International Journal of Biological Macromolecules, vol. 265, pp. 131069-131069.
View/Download from: Publisher's site

Singh, M, De Rubis, G, Kokkinis, S, Paudel, KR, Yeung, S, Hansbro, PM, Oliver, BGG & Dua, K 2024, 'Curcumin-Loaded Liposomes modulating the synergistic role of EpCAM and Estrogen Receptor Alpha in Lung Cancer Management', Pathology - Research and Practice, pp. 155317-155317.
View/Download from: Publisher's site

Singh, S, Saxena, S, Sharma, H, Paudel, KR, Chakraborty, A, MacLoughlin, R, Oliver, BG, Gupta, G, Negi, P, Singh, SK & Dua, K 2024, 'Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer', Pathology - Research and Practice, vol. 256, pp. 155222-155222.
View/Download from: Publisher's site

Solanki, N, Gupta, G, Chellappan, DK, Singh, SK, Gulati, M, Paudel, KR, Hansbro, PM, Dua, K, Bhan, S, Saini, M & Dureja, H 2024, 'Boswellic Acids: A Critical Appraisal of Their Therapeutic and Nutritional Benefits in Chronic Inflammatory Diseases', Endocrine, Metabolic & Immune Disorders - Drug Targets, vol. 24, no. 1, pp. 116-129.
View/Download from: Publisher's site
View description>>

Background:In the last few decades, it has been largely perceived that the factors affecting the immune system and its varying pathways lead to the pathological progression of inflammation and inflammatory conditions. Chronic inflammation also contributes to common diseases, such as diabetes mellitus, ischemic heart disease, cancer, chronic renal inflammatory disease, non-alcoholic fatty hepat-ic disease, autoimmune diseases and neurodegenerative diseases.Objective:Interestingly, plant sources and secondary metabolites from plants have been increasingly employed in managing acute and chronic inflammatory diseases for centuries. Boswellic acids are pentacyclic triterpenoidal moieties obtained from the oleo gum resin of different Boswellia species.Methods:Detailed data was collected revealing the anti-inflammatory potential of Boswellic acids through various databases.Results:These are pharmacologically active agents that possess promising anti-inflammatory, anti-arthritic, antirheumatic, anti-diarrheal, anti-hyperlipidemic, anti-asthmatic, anti-cancer, and anti-microbial effects.Conclusion:Boswellic acids have been in use since ancient times primarily to treat acute and chronic inflammatory diseases. This review discusses the various mechanisms underlying the inflammatory process and the necessity of such natural products as a medication to treat inflammatory diseases. In addition, a discussion has also been extended to understand the primary targets involved in inflamma-tion. The review further explores the therapeutic potential of boswellic acids in

Thapa, R, Afzal, M, Goyal, A, Gupta, G, Bhat, AA, Almalki, WH, Kazmi, I, Alzarea, SI, Shahwan, M, Kukreti, N, Ali, H, Dureja, H, Kumar, P, Singh, TG, Kuppusamy, G, Singh, SK & Dua, K 2024, 'Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics', Life Sciences, vol. 345, pp. 122613-122613.
View/Download from: Publisher's site

Thapa, R, Afzal, O, Afzal, M, Gupta, G, Bhat, AA, Hassan almalki, W, Kazmi, I, Alzarea, SI, Saleem, S, Arora, P, Singh, SK & Dua, K 2024, 'From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression', Pathology - Research and Practice, vol. 253, pp. 154959-154959.
View/Download from: Publisher's site

Yin, M, Wadhwa, R, Marshall, JE, Gillis, CM, Kim, RY, Dua, K, Palsson-McDermott, EM, Fallon, PG, Hansbro, PM & O’Neill, LAJ 2024, '4-Octyl Itaconate Alleviates Airway Eosinophilic Inflammation by Suppressing Chemokines and Eosinophil Development', The Journal of Immunology, vol. 212, no. 1, pp. 13-23.
View/Download from: Publisher's site
View description>>

Abstract 4-Octyl itaconate (4-OI) is a derivative of the Krebs cycle–derived metabolite itaconate and displays an array of antimicrobial and anti-inflammatory properties through modifying cysteine residues within protein targets. We have found that 4-OI significantly reduces the production of eosinophil-targeted chemokines in a variety of cell types, including M1 and M2 macrophages, Th2 cells, and A549 respiratory epithelial cells. Notably, the suppression of these chemokines in M1 macrophages was found to be NRF2-dependent. In addition, 4-OI can interfere with IL-5 signaling and directly affect eosinophil differentiation. In a model of eosinophilic airway inflammation in BALB/c mice, 4-OI alleviated airway resistance and reduced eosinophil recruitment to the lungs. Our findings suggest that itaconate derivatives could be promising therapeutic agents for the treatment of eosinophilic asthma.